Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data

Riccardo Lencioni, Thierry de Baere, Michael C. Soulen, William S. Rilling, Jean Francois H Geschwind

Research output: Contribution to journalReview article

115 Citations (Scopus)

Abstract

Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the administration of an anticancer-in-oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta-analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980 and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on predefined inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 articles, including a total of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis. Objective response rate was 52.5% (95% confidence interval [CI]: 43.6-61.5). Overall survival (OS) was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median OS was 19.4 months (95% CI: 16.2-22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with postembolization syndrome. Overall mortality rate was 0.6% and the most common cause of death was related to acute liver insufficiency. Conclusions: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. (Hepatology 2016;64:106–116).

Original languageEnglish (US)
Pages (from-to)106-116
Number of pages11
JournalHepatology
Volume64
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Ethiodized Oil
Hepatocellular Carcinoma
Safety
Survival
Randomized Controlled Trials
Confidence Intervals
Hepatic Insufficiency
Gastroenterology
Emulsions
MEDLINE
Publications
Meta-Analysis
Cause of Death
Oils
Databases
Mortality
Liver
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. F. H. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 64(1), 106-116. https://doi.org/10.1002/hep.28453

Lipiodol transarterial chemoembolization for hepatocellular carcinoma : A systematic review of efficacy and safety data. / Lencioni, Riccardo; de Baere, Thierry; Soulen, Michael C.; Rilling, William S.; Geschwind, Jean Francois H.

In: Hepatology, Vol. 64, No. 1, 01.07.2016, p. 106-116.

Research output: Contribution to journalReview article

Lencioni, R, de Baere, T, Soulen, MC, Rilling, WS & Geschwind, JFH 2016, 'Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data', Hepatology, vol. 64, no. 1, pp. 106-116. https://doi.org/10.1002/hep.28453
Lencioni, Riccardo ; de Baere, Thierry ; Soulen, Michael C. ; Rilling, William S. ; Geschwind, Jean Francois H. / Lipiodol transarterial chemoembolization for hepatocellular carcinoma : A systematic review of efficacy and safety data. In: Hepatology. 2016 ; Vol. 64, No. 1. pp. 106-116.
@article{7c2e05e7c95348ddb4dcac9c1d4bef03,
title = "Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data",
abstract = "Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the administration of an anticancer-in-oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta-analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980 and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on predefined inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 articles, including a total of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis. Objective response rate was 52.5{\%} (95{\%} confidence interval [CI]: 43.6-61.5). Overall survival (OS) was 70.3{\%} at 1 year, 51.8{\%} at 2 years, 40.4{\%} at 3 years, and 32.4{\%} at 5 years. Median OS was 19.4 months (95{\%} CI: 16.2-22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with postembolization syndrome. Overall mortality rate was 0.6{\%} and the most common cause of death was related to acute liver insufficiency. Conclusions: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. (Hepatology 2016;64:106–116).",
author = "Riccardo Lencioni and {de Baere}, Thierry and Soulen, {Michael C.} and Rilling, {William S.} and Geschwind, {Jean Francois H}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/hep.28453",
language = "English (US)",
volume = "64",
pages = "106--116",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Lipiodol transarterial chemoembolization for hepatocellular carcinoma

T2 - A systematic review of efficacy and safety data

AU - Lencioni, Riccardo

AU - de Baere, Thierry

AU - Soulen, Michael C.

AU - Rilling, William S.

AU - Geschwind, Jean Francois H

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the administration of an anticancer-in-oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta-analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980 and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on predefined inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 articles, including a total of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis. Objective response rate was 52.5% (95% confidence interval [CI]: 43.6-61.5). Overall survival (OS) was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median OS was 19.4 months (95% CI: 16.2-22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with postembolization syndrome. Overall mortality rate was 0.6% and the most common cause of death was related to acute liver insufficiency. Conclusions: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. (Hepatology 2016;64:106–116).

AB - Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the administration of an anticancer-in-oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta-analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980 and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on predefined inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 articles, including a total of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis. Objective response rate was 52.5% (95% confidence interval [CI]: 43.6-61.5). Overall survival (OS) was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median OS was 19.4 months (95% CI: 16.2-22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with postembolization syndrome. Overall mortality rate was 0.6% and the most common cause of death was related to acute liver insufficiency. Conclusions: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. (Hepatology 2016;64:106–116).

UR - http://www.scopus.com/inward/record.url?scp=84976491670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976491670&partnerID=8YFLogxK

U2 - 10.1002/hep.28453

DO - 10.1002/hep.28453

M3 - Review article

C2 - 26765068

AN - SCOPUS:84976491670

VL - 64

SP - 106

EP - 116

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -